Our data demonstrated a risk of 0.087% for the development of NAION in patients with type 2 diabetes mellitus treated with GLP-1 therapy; in the clinical context, the risk for NAION is much lower than for cerebrovascular accidents, myocardial infarction, heart failure, chronic kidney disease, and all-cause mortality [45-52]. Here, GLP1R is linked to type 2 diabetes mellitus.